One of the most dreaded feelings for an investor is when the stock they just bought is overvalued, or they missed out on an undervalued opportunity by not acting fast enough.

But what if you had the insights to effectively evaluate a company like Emergent Biosolutions Inc before investing? Investing requires a certain perspective to avoid being overly confident in a company or worried about cyclical changes. A smart way to take the guesswork out of knowing when to buy or sell Emergent Biosolutions Inc’s stock is to have the right tools and resources as well as a clear monitoring process.

In this article, we go over a few key elements for understanding Emergent Biosolutions Inc’s stock price such as:

• Current stock price and volume
• Stock price history
• Upgrades and downgrades from analysts
• Stock price momentum as measured by its relative strength

About Emergent Biosolutions Inc (EBS)

Before we jump into Emergent Biosolutions Inc’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Emergent BioSolutions, Inc. is a life sciences company focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats (PHTs). The Company is focused on five PHT categories: chemical, biological, radiological, nuclear and explosives (CBRNE); emerging infectious diseases; travel health; public health crises (such as the opioid crisis and the COVID-19 pandemic); acute, emergency, and community care. Its business lines include Medical Countermeasures (MCM), Commercial and CDMO. MCM focuses primarily on procurement of MCM products and procured product candidates by domestic and international government customers. It provides solutions for PHTs through a portfolio of vaccines and therapeutics that it develops and manufactures for governments and consumers. It offers TEMBEXA (brincidofovir) an antiviral for the treatment of smallpox in all age groups, including adults, and for patients who have difficulty swallowing.

Want to learn more about Emergent Biosolutions Inc’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Emergent Biosolutions Inc. The AAII Stock Evaluator puts a company’s grades, charts, news, financials, valuation, ratios, filings and more at your fingertips.

Emergent Biosolutions Inc’s Stock Price as of Market Close

As of February 15, 2023, 4:00 PM CST, Emergent Biosolutions Inc’s stock price was $14.92.

Emergent Biosolutions Inc is up 12.52% from its previous closing price of $13.26.

During the last market session, Emergent Biosolutions Inc’s stock traded between $12.87 and $13.36. Currently, there are 49.90 million shares of Emergent Biosolutions Inc stock available for purchase.

Emergent Biosolutions Inc’s price-earnings (P/E) ratio is currently at 16.2, which is low compared to the Pharmaceuticals industry median of 20.3. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

Emergent Biosolutions Inc Stock Price History

Emergent Biosolutions Inc’s (EBS) price is currently up 13.12% so far this month.

During the month of February, Emergent Biosolutions Inc’s stock price has reached a high of $14.95 and a low of $12.60.

Over the last year, Emergent Biosolutions Inc has hit prices as high as $45.62 and as low as $10.61. Year to date, Emergent Biosolutions Inc’s stock is down 65.68%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Emergent Biosolutions Inc Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

One of the most common factors that can drastically impact a stock’s price is analyst upgrades and downgrades. When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of February 14, 2023, there were 0 analysts who downgraded Emergent Biosolutions Inc’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Emergent Biosolutions Inc’s financial health and valuation. It is possible for a stock to appear cheap based on one valuation metric but appear expensive on another. It is also possible for one valuation ratio to be associated with outperforming stocks during certain periods of time but not others.

Therefore, AAII developed a composite valuation to help resolve such issues. AAII’s Value Grade analyzes six distinct variables: price-to-sales (P/S) ratio, price-earnings (P/E) ratio, the ratio of enterprise value to earnings before interest, taxes, depreciation and amortization (EV/EBITDA), shareholder yield, price-to-book-value (P/B) ratio and price-to-free-cash-flow (P/FCF) ratio.

Emergent Biosolutions Inc’s current valuation based on AAII’s Value Grade is a A, which means it is considered to be Deep Value.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Emergent Biosolutions Inc (EBS) by visiting AAII Stock Evaluator.

Relative Price Strength of Emergent Biosolutions Inc

Relative price strength addresses the relationship between a stock price’s trend and the price trend of the market. This ratio is expressed as a percentage and helps investors understand a company’s momentum as well as its value. You can use relative price strength to select investments that have been outperforming the market or a specific benchmark.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. The weighted four-quarter relative price strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40%, and each of the three previous quarters are given a weighting of 20%.

As of February 14, 2023, Emergent Biosolutions Inc has a weighted four-quarter relative price strength of -19.15%, which translates to a Momentum Score of 13 and is considered to be Very Weak.

Want to learn more about how Emergent Biosolutions Inc is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Emergent Biosolutions Inc Stock Price: Bottom Line

As of February 15, 2023, Emergent Biosolutions Inc’s stock price is $14.92, which is up 12.52% from its previous closing price.

At AAII, we stress that investors should never buy or sell a stock solely based on its stock price. Past returns do not guarantee future performance. Therefore, you should consider multiple ratios, fundamentals and analytics before making a decision. Whether you decide it’s a good time to buy or sell Emergent Biosolutions Inc’s stock based on its stock price forecast is ultimately up to you.

It’s important to understand that stock prices are driven by a variety of factors, but ultimately the price at any given moment is due to the supply and demand in the market. Stock price overviews, like the one you just read, only give you a small snapshot of a company’s performance, value and momentum.

By becoming an A+ Investor subscriber, you will have full access to analytics, grades, stock screens, commentary and more so you can invest with confidence.